Teva Pharmaceutical Industries Limited (TLV: TEVA)
Israel
· Delayed Price · Currency is ILS · Price in ILA
6,762.00
+183.00 (2.78%)
Sep 12, 2024, 5:24 PM IDT
TEVA Revenue
Teva Pharmaceutical Industries had revenue of $4.16B USD in the quarter ending June 30, 2024, with 7.37% growth. This brings the company's revenue in the last twelve months to $16.29B, up 8.48% year-over-year. In the year 2023, Teva Pharmaceutical Industries had annual revenue of $15.85B with 6.17% growth.
Revenue (ttm)
$16.29B
Revenue Growth
+8.48%
P/S Ratio
1.24
Revenue / Employee
$446.64K
Employees
36,472
Market Cap
77.42B ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
Dec 31, 2019 | 16.89B | -1.38B | -7.57% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionTeva Pharmaceutical Industries News
- 2 days ago - Teva to Present at the Bank of America 2024 Global Healthcare Conference - GlobeNewsWire
- 3 days ago - Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial - Reuters
- 3 days ago - Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies - Benzinga
- 3 days ago - Teva facing EU fine for disparaging Copaxone rival: report - Seeking Alpha
- 3 days ago - Exclusive: Teva faces EU fine for disparaging rival multiple sclerosis medicine, sources say - Reuters
- 4 days ago - Cheap Teva Stock Should Reward Patient Investors - Seeking Alpha
- 7 days ago - JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability - Benzinga
- 9 days ago - CareRx names Suzanne Brand as finance chief - Seeking Alpha